<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Oncol</journal-id><journal-title-group><journal-title>Clinical &amp; Translational Oncology</journal-title></journal-title-group><issn pub-type="ppub">1699-048X</issn><issn pub-type="epub">1699-3055</issn><publisher><publisher-name>Springer Milan</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22855138</article-id><article-id pub-id-type="pmc">3427491</article-id><article-id pub-id-type="publisher-id">843</article-id><article-id pub-id-type="doi">10.1007/s12094-012-0843-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Gravalos</surname><given-names>Cristina</given-names></name><address><phone>+34-650770415</phone><fax>+34-914603310</fax><email>cgravalos@telefonica.net</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Salut</surname><given-names>Antonieta</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>García-Girón</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>García-Carbonero</surname><given-names>Rocío</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>León</surname><given-names>Ana Isabel</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Sevilla</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Maurel</surname><given-names>Joan</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Esteban</surname><given-names>Beatriz</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>García-Rico</surname><given-names>Eduardo</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Murias</surname><given-names>Adolfo</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Cortés-Funes</surname><given-names>Hernán</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Medical Oncology Department, University Hospital 12 de Octubre, Avda. de Andalucía s/n Km 5.400, 28041 Madrid, Spain </aff><aff id="Aff2"><label>2</label>Hospital Arnau de la Villanova, Lleida, Spain </aff><aff id="Aff3"><label>3</label>Hospital General Yagüe, Burgos, Spain </aff><aff id="Aff4"><label>4</label>Hospital Severo Ochoa, Leganés, Spain </aff><aff id="Aff5"><label>5</label>Fundación Jiménez Díaz, Madrid, Spain </aff><aff id="Aff6"><label>6</label>Hospital Virgen de la Victoria, Málaga, Spain </aff><aff id="Aff7"><label>7</label>Hospital Clinic i Provincial, Barcelona, Spain </aff><aff id="Aff8"><label>8</label>Hospital General de Segovia, Segovia, Spain </aff><aff id="Aff9"><label>9</label>Hospital de Monteprincipe, Madrid, Spain </aff><aff id="Aff10"><label>10</label>Hospital Insular de Las Palmas, Gran Canaria, Spain </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>7</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>7</month><year>2012</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2012</year></pub-date><volume>14</volume><issue>8</issue><fpage>606</fpage><lpage>612</lpage><history><date date-type="received"><day>28</day><month>3</month><year>2011</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2011</year></date></history><permissions><copyright-statement>© The Author(s) 2012</copyright-statement></permissions><abstract id="Abs1"><sec><title><offsets xml_i="4579" xml_f="4591" txt_i="11" txt_f="23">Introduction</offsets></title><p><offsets xml_i="4602" xml_f="4720" txt_i="24" txt_f="142">The aim of this study was to compare TOMOX versus FOLFOX4 as first-line treatment of advanced colorectal cancer (CRC).</offsets></p></sec><sec><title><offsets xml_i="4742" xml_f="4763" txt_i="144" txt_f="165">Materials and methods</offsets></title><p><offsets xml_i="4774" xml_f="5020" txt_i="166" txt_f="412">191 chemotherapy-naïve patients were randomized to receive TOMOX or FOLFOX4. Patients were evaluated every 3 months and chemotherapy was continued until disease progression or unacceptable toxicity. Overall response rate was the primary endpoint.</offsets></p></sec><sec><title><offsets xml_i="5042" xml_f="5049" txt_i="414" txt_f="421">Results</offsets></title><p><offsets xml_i="5060" xml_f="5189" txt_i="422" txt_f="551">183 patients were included in the intent-to-treat analysis (92 TOMOX and 91 FOLFOX4). Overall response rate was 45.6 and 36.3 % (</offsets><italic><offsets xml_i="5197" xml_f="5198" txt_i="551" txt_f="552">p</offsets></italic><offsets xml_i="5207" xml_f="5352" txt_i="552" txt_f="697"> = 0.003) for TOMOX and FOLFOX4, respectively. No statistically significant differences were observed in overall survival (15.6 and 17.2 months; </offsets><italic><offsets xml_i="5360" xml_f="5361" txt_i="697" txt_f="698">p</offsets></italic><offsets xml_i="5370" xml_f="5428" txt_i="698" txt_f="756"> = 0.475); progression-free survival (7.7 and 8.7 months; </offsets><italic><offsets xml_i="5436" xml_f="5437" txt_i="756" txt_f="757">p</offsets></italic><offsets xml_i="5446" xml_f="5500" txt_i="757" txt_f="811"> = 0.292), and response duration (6.4 and 7.6 months; </offsets><italic><offsets xml_i="5508" xml_f="5509" txt_i="811" txt_f="812">p</offsets></italic><offsets xml_i="5518" xml_f="5593" txt_i="812" txt_f="887"> = 0.372) for TOMOX and FOLFOX4, respectively. Grades 3 and 4 neutropenia (</offsets><italic><offsets xml_i="5601" xml_f="5602" txt_i="887" txt_f="888">p</offsets></italic><offsets xml_i="5611" xml_f="5641" txt_i="888" txt_f="915"> &lt; 0.0001) and leukopenia (</offsets><italic><offsets xml_i="5649" xml_f="5650" txt_i="915" txt_f="916">p</offsets></italic><offsets xml_i="5659" xml_f="5777" txt_i="916" txt_f="1034"> = 0.028) were more common with the FOLFOX4 regimen, while hepatic disorders and asthenia were higher in TOMOX group (</offsets><italic><offsets xml_i="5785" xml_f="5786" txt_i="1034" txt_f="1035">p</offsets></italic><offsets xml_i="5795" xml_f="6143" txt_i="1035" txt_f="1383"> = ns). There were two treatment-related deaths in the FOLFOX4 arm and one in the TOMOX arm. Quality of life analysis based on the SF-36 revealed differences between the two regimens for physical and mental composite scores after 6 weeks, and for body pain and emotional role functioning after 6 and 12 weeks; all of these favored the FOLFOX4 arm (</offsets><italic><offsets xml_i="6151" xml_f="6152" txt_i="1383" txt_f="1384">p</offsets></italic><offsets xml_i="6161" xml_f="6170" txt_i="1384" txt_f="1393"> ≤ 0.05).</offsets></p></sec><sec><title><offsets xml_i="6192" xml_f="6203" txt_i="1395" txt_f="1406">Conclusions</offsets></title><p><offsets xml_i="6214" xml_f="6456" txt_i="1407" txt_f="1649">TOMOX and FOLFOX4 seem to have similar efficacy and are well tolerated in the first-line treatment for advanced CRC with different profiles of toxicity. The convenient TOMOX regimen may offer an alternative to fluoropyrimidine-based regimens.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Colorectal cancer</kwd><kwd>Raltitrexed</kwd><kwd>Oxaliplatin</kwd><kwd>Fluorouracil</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Federación de Sociedades Españolas de Oncología (FESEO) 2012</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="6908" xml_f="6920" txt_i="1658" txt_f="1670">Introduction</offsets></title><p><offsets xml_i="6931" xml_f="7114" txt_i="1671" txt_f="1854">Colorectal cancer (CRC) is the second most prevalent cancer worldwide, with more than 1 million new cases reported per year, accounting for 9.4 % of total cancers diagnosed globally [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="7146" xml_f="7147" txt_i="1854" txt_f="1855">1</offsets></xref><offsets xml_i="7154" xml_f="7265" txt_i="1855" txt_f="1966">]. In Europe, CRC is the second most commonly diagnosed cancer and accounts for 13 % of newly diagnosed cases [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="7297" xml_f="7298" txt_i="1966" txt_f="1967">2</offsets></xref><offsets xml_i="7305" xml_f="7423" txt_i="1967" txt_f="2085">]. Approximately 20–30 % of patients present with advanced disease. The prognosis for such patients is not promising [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="7455" xml_f="7456" txt_i="2085" txt_f="2086">3</offsets></xref><offsets xml_i="7463" xml_f="7667" txt_i="2086" txt_f="2290">], however, palliative chemotherapy increases overall survival (OS), progression-free survival (PFS) and improved quality of life (QoL) for patients with advanced CRC, compared with best supportive care [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="7699" xml_f="7700" txt_i="2290" txt_f="2291">4</offsets></xref><offsets xml_i="7707" xml_f="7709" txt_i="2291" txt_f="2293">, </offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="7741" xml_f="7742" txt_i="2293" txt_f="2294">5</offsets></xref><offsets xml_i="7749" xml_f="7751" txt_i="2294" txt_f="2296">].</offsets></p><p><offsets xml_i="7758" xml_f="7868" txt_i="2297" txt_f="2407">For more than 40 years, 5-fluorouracil (5-FU)-based chemotherapy was the only treatment with activity in CRC [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="7900" xml_f="7901" txt_i="2407" txt_f="2408">6</offsets></xref><offsets xml_i="7908" xml_f="7910" txt_i="2408" txt_f="2410">, </offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="7942" xml_f="7943" txt_i="2410" txt_f="2411">7</offsets></xref><offsets xml_i="7950" xml_f="8250" txt_i="2411" txt_f="2711">]. However, during the last 10 years, a number of drugs have been demonstrated activity for advanced CRC. Oxaliplatin in combination with bimonthly 5-FU/leucovorin (LV) has been shown to be superior to 5-FU/LV in terms of response rate (RR) and PFS without having a negative impact on patients’ QoL [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="8282" xml_f="8283" txt_i="2711" txt_f="2712">8</offsets></xref><offsets xml_i="8290" xml_f="8487" txt_i="2712" txt_f="2909">]. Regimens based on the De Gramont schedule combined with oxaliplatin (FOLFOX) administrated every 14 days are considered to be standard options of chemotherapy for the treatment of advanced CRC [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="8519" xml_f="8520" txt_i="2909" txt_f="2910">9</offsets></xref><offsets xml_i="8527" xml_f="8529" txt_i="2910" txt_f="2912">, </offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="8562" xml_f="8564" txt_i="2912" txt_f="2914">10</offsets></xref><offsets xml_i="8571" xml_f="8730" txt_i="2914" txt_f="3073">], but may be unsuitable for some patients owing to the toxicity profile and inconvenient administration as it requires a central venous catheter implantation.</offsets></p><p><offsets xml_i="8737" xml_f="8757" txt_i="3074" txt_f="3094">Raltitrexed (Tomudex</offsets><sup><offsets xml_i="8762" xml_f="8763" txt_i="3094" txt_f="3095">®</offsets></sup><offsets xml_i="8769" xml_f="9047" txt_i="3095" txt_f="3373">) is a specific inhibitor of thymidylate synthase (TS). Raltitrexed enters cells via the reduced-folate carrier and is polyglutamated by folylpolyglutamate synthase, which increases intracellular retention and leads to prolonged TS inhibition, DNA fragmentation and cell death [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="9080" xml_f="9082" txt_i="3373" txt_f="3375">11</offsets></xref><offsets xml_i="9089" xml_f="9091" txt_i="3375" txt_f="3377">, </offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="9124" xml_f="9126" txt_i="3377" txt_f="3379">12</offsets></xref><offsets xml_i="9133" xml_f="9257" txt_i="3379" txt_f="3503">]. The mechanism of action of raltitrexed differs from that of 5-FU and its serum terminal half life is longer (148–379 h) [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="9290" xml_f="9292" txt_i="3503" txt_f="3505">13</offsets></xref><offsets xml_i="9299" xml_f="9395" txt_i="3505" txt_f="3601">], which allows raltitrexed to be administered with an extended dosing interval, every 3 weeks [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="9428" xml_f="9430" txt_i="3601" txt_f="3603">11</offsets></xref><offsets xml_i="9437" xml_f="9439" txt_i="3603" txt_f="3605">].</offsets></p><p><offsets xml_i="9446" xml_f="9606" txt_i="3606" txt_f="3766">As a single agent, raltitrexed has been extensively studied in four large comparative clinical trials that included more than 2,000 patients with advanced CRC [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="9639" xml_f="9641" txt_i="3766" txt_f="3768">14</offsets></xref><offsets xml_i="9648" xml_f="9649" txt_i="3768" txt_f="3769">–</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="9682" xml_f="9684" txt_i="3769" txt_f="3771">17</offsets></xref><offsets xml_i="9691" xml_f="9739" txt_i="3771" txt_f="3819">]. In three of these studies, raltitrexed 3 mg/m</offsets><sup><offsets xml_i="9744" xml_f="9745" txt_i="3819" txt_f="3820">2</offsets></sup><offsets xml_i="9751" xml_f="9904" txt_i="3820" txt_f="3973"> every 3 weeks was compared with 5-FU or 5-FU/LV, no statistically significant differences were found in RR or survival outcomes between treatment arms [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="9937" xml_f="9939" txt_i="3973" txt_f="3975">14</offsets></xref><offsets xml_i="9946" xml_f="9947" txt_i="3975" txt_f="3976">–</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="9980" xml_f="9982" txt_i="3976" txt_f="3978">16</offsets></xref><offsets xml_i="9989" xml_f="10149" txt_i="3978" txt_f="4138">]. In a fourth study, reported only as an abstract, a significantly longer median OS for 5-FU/LV was observed compared with raltitrexed at dosing of 3 or 4 mg/m</offsets><sup><offsets xml_i="10154" xml_f="10155" txt_i="4138" txt_f="4139">2</offsets></sup><offsets xml_i="10161" xml_f="10163" txt_i="4139" txt_f="4141"> [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="10196" xml_f="10198" txt_i="4141" txt_f="4143">17</offsets></xref><offsets xml_i="10205" xml_f="10349" txt_i="4143" txt_f="4287">]. Raltitrexed generally had an acceptable tolerability profile, and was associated with less leukopenia and mucositis/stomatitis than 5-FU/LV [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="10382" xml_f="10384" txt_i="4287" txt_f="4289">14</offsets></xref><offsets xml_i="10391" xml_f="10393" txt_i="4289" txt_f="4291">, </offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="10426" xml_f="10428" txt_i="4291" txt_f="4293">15</offsets></xref><offsets xml_i="10435" xml_f="10437" txt_i="4293" txt_f="4295">, </offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="10470" xml_f="10472" txt_i="4295" txt_f="4297">17</offsets></xref><offsets xml_i="10479" xml_f="10574" txt_i="4297" txt_f="4392">], although increased toxicity of raltitrexed compared with 5-FU/LV was reported in one study [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="10607" xml_f="10609" txt_i="4392" txt_f="4394">16</offsets></xref><offsets xml_i="10616" xml_f="10650" txt_i="4394" txt_f="4428">]. In the trial by Pazdur et al. [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="10683" xml_f="10685" txt_i="4428" txt_f="4430">17</offsets></xref><offsets xml_i="10692" xml_f="10773" txt_i="4430" txt_f="4511">] high rate of toxic death was observed when the dosing of raltitrexed was 4 mg/m</offsets><sup><offsets xml_i="10778" xml_f="10779" txt_i="4511" txt_f="4512">2</offsets></sup><offsets xml_i="10785" xml_f="10786" txt_i="4512" txt_f="4513">.</offsets></p><p><offsets xml_i="10793" xml_f="11174" txt_i="4514" txt_f="4895">Young et al. evaluated patient preferences between raltitrexed and 5-FU-based chemotherapy regimens, regarding to adverse events and administration schedules in 82 patients with advanced CRC. Showing a similar efficacy, patients showed preferences for raltitrexed over other regimens, based its administration schedule (15-min intravenous every weeks) and/or side effects profile [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="11207" xml_f="11209" txt_i="4895" txt_f="4897">18</offsets></xref><offsets xml_i="11216" xml_f="11218" txt_i="4897" txt_f="4899">].</offsets></p><p><offsets xml_i="11225" xml_f="11524" txt_i="4900" txt_f="5199">The extended dosing interval of raltitrexed, together with the different mechanisms of action of raltitrexed and oxaliplatin, has led to clinical interest in combining the two drugs. Raltitrexed in combination with oxaliplatin (TOMOX) has been evaluated in several preclinical and clinical studies [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="11557" xml_f="11559" txt_i="5199" txt_f="5201">19</offsets></xref><offsets xml_i="11566" xml_f="11567" txt_i="5201" txt_f="5202">–</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="11600" xml_f="11602" txt_i="5202" txt_f="5204">21</offsets></xref><offsets xml_i="11609" xml_f="11780" txt_i="5204" txt_f="5375">]. Based on a phase I/II dose–escalation trial, the optimal dose of raltitrexed and oxaliplatin to be used in the TOMOX combination was established as oxaliplatin 130 mg/m</offsets><sup><offsets xml_i="11785" xml_f="11786" txt_i="5375" txt_f="5376">2</offsets></sup><offsets xml_i="11792" xml_f="11825" txt_i="5376" txt_f="5409"> combined with raltitrexed 3 mg/m</offsets><sup><offsets xml_i="11830" xml_f="11831" txt_i="5409" txt_f="5410">2</offsets></sup><offsets xml_i="11837" xml_f="11853" txt_i="5410" txt_f="5426"> every 3 weeks [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="11886" xml_f="11888" txt_i="5426" txt_f="5428">19</offsets></xref><offsets xml_i="11895" xml_f="12008" txt_i="5428" txt_f="5541">]. In phase II studies of this combination regimen, TOMOX has shown promising RR, survival and toxicity results [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="12041" xml_f="12043" txt_i="5541" txt_f="5543">21</offsets></xref><offsets xml_i="12050" xml_f="12051" txt_i="5543" txt_f="5544">–</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="12084" xml_f="12086" txt_i="5544" txt_f="5546">25</offsets></xref><offsets xml_i="12093" xml_f="12319" txt_i="5546" txt_f="5772">]. These studies have provided evidence that the TOMOX combination may be effective and well tolerated in patients with advanced CRC, and have provided rationale for further evaluation of the regimen in the first-line setting.</offsets></p><p><offsets xml_i="12326" xml_f="12467" txt_i="5773" txt_f="5914">This randomized phase II trial was designed to determine whether TOMOX is as effective as FOLFOX in the first-line treatment of advanced CRC.</offsets></p></sec><sec id="Sec2" sec-type="materials|methods"><title><offsets xml_i="12528" xml_f="12549" txt_i="5916" txt_f="5937">Materials and methods</offsets></title><sec id="Sec3"><title><offsets xml_i="12579" xml_f="12587" txt_i="5938" txt_f="5946">Patients</offsets></title><p><offsets xml_i="12598" xml_f="14248" txt_i="5947" txt_f="7591">Patients were ≥18 years with advanced, histologically or cytologically confirmed, non-resectable metastatic CRC with bi-dimensionally measurable disease, life expectancy ≥3 months, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, adequate bone marrow (platelet count ≥100,000/L, neutrophil count ≥2,000 cells/L, and hemoglobin level ≥9.0 mg/dL), renal [serum creatinine concentration &lt;1.25× upper limit of normal (ULN) and creatinine clearance (CrCl) &gt;65 mL/min] and hepatic (serum bilirubin level ≤1.5× ULN, aspartate amino transferase and alanine amino transferase ≤2.5× ULN, and alkaline phosphatase ≤5× ULN) function. Exclusion criteria included previous chemotherapy for advanced disease (or adjuvant chemotherapy ≤6 months before enrollment), treatment with an experimental drug within 4 weeks of inclusion, uncontrolled intercurrent disease, bone metastases as the only manifestation of the disease, any malignancy within 5 years of study entry (except for adequately treated non-melanoma skin cancer or in-situ cervical carcinoma) and grade ≥2 peripheral neuropathy according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTC) version 2.0. Pretreatment assessments included complete medical history, physical examination, performance status, complete blood count, serum chemistry, electrocardiogram, and baseline measurement of tumor size based on tomography scans (CT). The study was carried out in compliance with the Declaration of Helsinki, Good Clinical Practice Guidelines, and all applicable local regulatory requirements. Signed informed consent was obtained from all patients.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="14280" xml_f="14292" txt_i="7593" txt_f="7605">Study design</offsets></title><p><offsets xml_i="14303" xml_f="14604" txt_i="7606" txt_f="7907">In this phase II, multicenter, open-label study, patients were randomized centrally in a 1:1 ratio to receive FOLFOX4 or TOMOX. Randomization was carried out using a four patient block randomization system at each study site, centrally administrated. FOLFOX4 was administered as previously described [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="14636" xml_f="14637" txt_i="7907" txt_f="7908">8</offsets></xref><offsets xml_i="14644" xml_f="14666" txt_i="7908" txt_f="7930">]: leucovorin 200 mg/m</offsets><sup><offsets xml_i="14671" xml_f="14672" txt_i="7930" txt_f="7931">2</offsets></sup><offsets xml_i="14678" xml_f="14699" txt_i="7931" txt_f="7952">, bolus 5-FU 400 mg/m</offsets><sup><offsets xml_i="14704" xml_f="14705" txt_i="7952" txt_f="7953">2</offsets></sup><offsets xml_i="14711" xml_f="14758" txt_i="7953" txt_f="8000"> plus 22-h continuous infusion of 5-FU 600 mg/m</offsets><sup><offsets xml_i="14763" xml_f="14764" txt_i="8000" txt_f="8001">2</offsets></sup><offsets xml_i="14770" xml_f="14805" txt_i="8001" txt_f="8036"> days 1–2, and oxaliplatino 85 mg/m</offsets><sup><offsets xml_i="14810" xml_f="14811" txt_i="8036" txt_f="8037">2</offsets></sup><offsets xml_i="14817" xml_f="14895" txt_i="8037" txt_f="8115"> day 1, every 2 weeks. Patients in the TOMOX group received raltitrexed 3 mg/m</offsets><sup><offsets xml_i="14900" xml_f="14901" txt_i="8115" txt_f="8116">2</offsets></sup><offsets xml_i="14907" xml_f="14975" txt_i="8116" txt_f="8184"> as a 15-min infusion, followed 45 min later by oxaliplatin 130 mg/m</offsets><sup><offsets xml_i="14980" xml_f="14981" txt_i="8184" txt_f="8185">2</offsets></sup><offsets xml_i="14987" xml_f="15398" txt_i="8185" txt_f="8593"> as a 2-h infusion, on day 1 of 3-week cycles. Raltitrexed dose and administration schedules were adjusted according to CrCl on day 1 of each cycle (CrCl &gt;65 mL/min: 100 % of planned dose every 3 weeks; CrCl = 55–65 mL/min: 75 % of planned dose every 4 weeks; CrCl = 25–54 mL/min: 50 % of planned dose every 4 weeks). If raltitrexed administration was delayed, administration of oxaliplatin was also delayed.</offsets></p><p><offsets xml_i="15405" xml_f="15808" txt_i="8594" txt_f="8997">Tolerability was evaluated at baseline and before each cycle. All toxicities graded according to the NCI-CTC version 2.0 except peripheral neuropathy that was evaluated according with the Sanofi classification. Dose adjustments and administration delays were evaluated based on the each patient’s most severe toxicity. In FOLFOX4 group, bolus and continuous infusion 5-FU was reduced to 300 and 500 mg/m</offsets><sup><offsets xml_i="15813" xml_f="15814" txt_i="8997" txt_f="8998">2</offsets></sup><offsets xml_i="15820" xml_f="15970" txt_i="8998" txt_f="9148">, respectively, if neutropenia, thrombocytopenia, diarrhea, stomatitis, or other toxicities grade (G) 3–4 occurred. Oxaliplatin was reduced to 65 mg/m</offsets><sup><offsets xml_i="15975" xml_f="15976" txt_i="9148" txt_f="9149">2</offsets></sup><offsets xml_i="15982" xml_f="16274" txt_i="9149" txt_f="9441"> in case of paresthesias associated with pain or functional less lasted during 7–14 days, and it was stopped if longer. In the TOMOX regimen, in case of neutropenia or thrombocytopenia G3 or G4, raltitrexed was reduced to 75 or 50 %, respectively, and oxaliplatin was administered at 100 mg/m</offsets><sup><offsets xml_i="16279" xml_f="16280" txt_i="9441" txt_f="9442">2</offsets></sup><offsets xml_i="16286" xml_f="16473" txt_i="9442" txt_f="9629">. Regarding non-hematological toxicities, in case of diarrhea, or stomatitis G2, G3 or G4 raltitrexed was reduced at 75, 50 % or omitted, respectively. Oxaliplatin was reduced to 100 mg/m</offsets><sup><offsets xml_i="16478" xml_f="16479" txt_i="9629" txt_f="9630">2</offsets></sup><offsets xml_i="16485" xml_f="16601" txt_i="9630" txt_f="9746"> in case of paresthesias associated with pain or functional less lasted during 7–14 days, and was stopped if longer.</offsets></p><p><offsets xml_i="16608" xml_f="17073" txt_i="9747" txt_f="10212">In both groups, treatment was continued until progressive disease (PD), death, withdrawal of informed consent, or unacceptable toxicity. In patients who achieved a complete response, treatment was continued for a maximum of 6 months with or without oxaliplatin, depending on degree of cumulative neurotoxicity. Prophylactic anti-emetics were administered according to normal clinical practice. Routine use of a granulocyte colony-stimulating factor was not allowed.</offsets></p><p><offsets xml_i="17080" xml_f="17157" txt_i="10213" txt_f="10290">QoL was assessed every 6 weeks using the short form-36 (SF-36) questionnaire.</offsets></p><p><offsets xml_i="17164" xml_f="17716" txt_i="10291" txt_f="10843">The primary objective of the study was to demonstrate the non-inferiority of TOMOX when compared with FOLFOX4 in terms of Objective Response Rate (ORR). To avoid bias, response was evaluated according to RECIST every 3 months, regardless of the number of cycles administrated. The secondary objectives included OS, PFS, response duration, tolerability and QoL. OS and PFS were assessed from date of randomization until progression (PD), death or last follow-up. Response duration was defined as date of first response until PD, death or last follow-up.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="17748" xml_f="17768" txt_i="10845" txt_f="10865">Statistical analysis</offsets></title><p><offsets xml_i="17779" xml_f="18264" txt_i="10866" txt_f="11351">Determination of sample size was based on the primary endpoint. Based on previously published data, the ORR for both regimens was expected to be ~50 %. The study was designed to detect a 12 % as a maximum difference for non-inferiority in ORR between the two arms, using α of 0.05 and a β of 0.20. To achieve this, the number of patients required was 430 (215 per group). Intergroup comparisons of ORR ±95 % confidence intervals (CI) were conducted using a normal asymptotic one-sided </offsets><italic><offsets xml_i="18272" xml_f="18273" txt_i="11351" txt_f="11352">Z</offsets></italic><offsets xml_i="18282" xml_f="18432" txt_i="11352" txt_f="11502"> test for proportions (non-inferiority) on independent samples. Univariate analyses of OS and PFS were conducted according to Kaplan–Meier estimates [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="18465" xml_f="18467" txt_i="11502" txt_f="11504">26</offsets></xref><offsets xml_i="18474" xml_f="18609" txt_i="11504" txt_f="11639">]. Comparisons between survival distributions were made by Cox proportional hazards model regressions, hazard ratios (HR) and 95 % CI [</offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="18642" xml_f="18644" txt_i="11639" txt_f="11641">27</offsets></xref><offsets xml_i="18651" xml_f="18694" txt_i="11641" txt_f="11684">]. Statistical significance was defined as </offsets><italic><offsets xml_i="18702" xml_f="18703" txt_i="11684" txt_f="11685">p</offsets></italic><offsets xml_i="18712" xml_f="18808" txt_i="11685" txt_f="11781"> ≤ 0.05. The limit for non-inferiority was established in 12 % applied to the HR 95 % CI limits.</offsets></p></sec></sec><sec id="Sec6" sec-type="results"><title><offsets xml_i="18865" xml_f="18872" txt_i="11784" txt_f="11791">Results</offsets></title><sec id="Sec7"><title><offsets xml_i="18902" xml_f="18910" txt_i="11792" txt_f="11800">Patients</offsets></title><p><offsets xml_i="18921" xml_f="19344" txt_i="11801" txt_f="12224">This phase II, multicenter, open-label, randomized study was conducted at 35 Spanish hospitals between January 2002 and February 2004. Due to limited funding, the study was closed prematurely for enrollment after 191 patients had been randomized. A total of 183 patients received at least one dose of study medication and were included in the intent-to-treat population (91 in the FOLFOX4 arm and 92 in the TOMOX arm; Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="19376" xml_f="19377" txt_i="12224" txt_f="12225">1</offsets></xref><offsets xml_i="19384" xml_f="19642" txt_i="12225" txt_f="12483">). Eight patients were excluded prior to receiving study medication due to; renal function out of range (2 patients), hematological function out of range (2 patients), hepatic and renal function out of range (2 patients) and for unknown reasons (2 patients).</offsets><fig id="Fig1"><label><offsets xml_i="19664" xml_f="19670" txt_i="12483" txt_f="12489">Fig. 1</offsets></label><caption><p><offsets xml_i="19690" xml_f="19713" txt_i="12489" txt_f="12512">Disposition of patients</offsets></p></caption><graphic xlink:href="12094_2012_843_Fig1_HTML" id="MO1"></graphic></fig></p><p><offsets xml_i="19806" xml_f="19966" txt_i="12514" txt_f="12674">Baseline demographics were similar between the two treatment groups, with no significant imbalances in sex, age, ECOG score or number of organs involved (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="20000" xml_f="20001" txt_i="12674" txt_f="12675">1</offsets></xref><offsets xml_i="20008" xml_f="20227" txt_i="12675" txt_f="12894">). However, there was a significant difference between the groups with respect to location of primary tumor; there was a higher prevalence of rectal tumors in the TOMOX group than in the FOLFOX4 group (43.5 vs. 24.2 %; </offsets><italic><offsets xml_i="20235" xml_f="20236" txt_i="12894" txt_f="12895">p</offsets></italic><offsets xml_i="20245" xml_f="20255" txt_i="12895" txt_f="12905"> = 0.005).</offsets><table-wrap id="Tab1"><label><offsets xml_i="20284" xml_f="20291" txt_i="12905" txt_f="12912">Table 1</offsets></label><caption><p><offsets xml_i="20311" xml_f="20368" txt_i="12912" txt_f="12969">Baseline characteristic of patients included in the study</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"><offsets xml_i="20459" xml_f="20473" txt_i="12970" txt_f="12984">Characteristic</offsets></th><th align="left" colspan="2"><offsets xml_i="20507" xml_f="20522" txt_i="12984" txt_f="12999">Treatment group</offsets></th><th align="left" rowspan="2"><italic><offsets xml_i="20564" xml_f="20565" txt_i="12999" txt_f="13000">p</offsets></italic><offsets xml_i="20574" xml_f="20580" txt_i="13000" txt_f="13006"> value</offsets></th></tr><tr><th align="left"><offsets xml_i="20611" xml_f="20620" txt_i="13006" txt_f="13015">FOLFOX4 (</offsets><italic><offsets xml_i="20628" xml_f="20629" txt_i="13015" txt_f="13016">n</offsets></italic><offsets xml_i="20638" xml_f="20644" txt_i="13016" txt_f="13022"> = 91)</offsets></th><th align="left"><offsets xml_i="20666" xml_f="20673" txt_i="13022" txt_f="13029">TOMOX (</offsets><italic><offsets xml_i="20681" xml_f="20682" txt_i="13029" txt_f="13030">n</offsets></italic><offsets xml_i="20691" xml_f="20697" txt_i="13030" txt_f="13036"> = 92)</offsets></th></tr></thead><tbody><tr><td align="left" colspan="4"><offsets xml_i="20755" xml_f="20760" txt_i="13036" txt_f="13041">Sex, </offsets><italic><offsets xml_i="20768" xml_f="20769" txt_i="13041" txt_f="13042">n</offsets></italic><offsets xml_i="20778" xml_f="20782" txt_i="13042" txt_f="13046"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="20813" xml_f="20818" txt_i="13047" txt_f="13052"> Male</offsets></td><td char="(" align="char"><offsets xml_i="20849" xml_f="20858" txt_i="13053" txt_f="13062">48 (52.7)</offsets></td><td char="(" align="char"><offsets xml_i="20889" xml_f="20898" txt_i="13063" txt_f="13072">56 (60.9)</offsets></td><td char="." align="char" rowspan="2"><offsets xml_i="20941" xml_f="20947" txt_i="13073" txt_f="13079">0.2674</offsets></td></tr><tr><td align="left"><offsets xml_i="20978" xml_f="20985" txt_i="13080" txt_f="13087"> Female</offsets></td><td char="(" align="char"><offsets xml_i="21016" xml_f="21025" txt_i="13088" txt_f="13097">43 (47.3)</offsets></td><td char="(" align="char"><offsets xml_i="21056" xml_f="21065" txt_i="13098" txt_f="13107">36 (39.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="21096" xml_f="21121" txt_i="13108" txt_f="13133">Median age, years (range)</offsets></td><td char="(" align="char"><offsets xml_i="21152" xml_f="21162" txt_i="13134" txt_f="13144">61 (35–82)</offsets></td><td char="(" align="char"><offsets xml_i="21193" xml_f="21203" txt_i="13145" txt_f="13155">65 (36–78)</offsets></td><td char="." align="char"><offsets xml_i="21234" xml_f="21240" txt_i="13156" txt_f="13162">0.6542</offsets></td></tr><tr><td align="left" colspan="4"><offsets xml_i="21283" xml_f="21310" txt_i="13163" txt_f="13190">Location of primary tumor, </offsets><italic><offsets xml_i="21318" xml_f="21319" txt_i="13190" txt_f="13191">n</offsets></italic><offsets xml_i="21328" xml_f="21332" txt_i="13191" txt_f="13195"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="21363" xml_f="21369" txt_i="13196" txt_f="13202"> Colon</offsets></td><td char="(" align="char"><offsets xml_i="21400" xml_f="21409" txt_i="13203" txt_f="13212">69 (75.8)</offsets></td><td char="(" align="char"><offsets xml_i="21440" xml_f="21449" txt_i="13213" txt_f="13222">52 (56.5)</offsets></td><td char="." align="char" rowspan="2"><offsets xml_i="21492" xml_f="21498" txt_i="13223" txt_f="13229">0.0058</offsets></td></tr><tr><td align="left"><offsets xml_i="21529" xml_f="21536" txt_i="13230" txt_f="13237"> Rectum</offsets></td><td char="(" align="char"><offsets xml_i="21567" xml_f="21576" txt_i="13238" txt_f="13247">22 (24.2)</offsets></td><td char="(" align="char"><offsets xml_i="21607" xml_f="21616" txt_i="13248" txt_f="13257">40 (43.5)</offsets></td></tr><tr><td align="left" colspan="4"><offsets xml_i="21659" xml_f="21671" txt_i="13258" txt_f="13270">ECOG score, </offsets><italic><offsets xml_i="21679" xml_f="21680" txt_i="13270" txt_f="13271">n</offsets></italic><offsets xml_i="21689" xml_f="21693" txt_i="13271" txt_f="13275"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="21724" xml_f="21726" txt_i="13276" txt_f="13278"> 0</offsets></td><td char="(" align="char"><offsets xml_i="21757" xml_f="21766" txt_i="13279" txt_f="13288">48 (52.7)</offsets></td><td char="(" align="char"><offsets xml_i="21797" xml_f="21806" txt_i="13289" txt_f="13298">51 (55.4)</offsets></td><td char="." align="char" rowspan="3"><offsets xml_i="21849" xml_f="21855" txt_i="13299" txt_f="13305">0.5544</offsets></td></tr><tr><td align="left"><offsets xml_i="21886" xml_f="21888" txt_i="13306" txt_f="13308"> 1</offsets></td><td char="(" align="char"><offsets xml_i="21919" xml_f="21928" txt_i="13309" txt_f="13318">39 (42.9)</offsets></td><td char="(" align="char"><offsets xml_i="21959" xml_f="21968" txt_i="13319" txt_f="13328">39 (42.4)</offsets></td></tr><tr><td align="left"><offsets xml_i="21999" xml_f="22001" txt_i="13329" txt_f="13331"> 2</offsets></td><td char="(" align="char"><offsets xml_i="22032" xml_f="22039" txt_i="13332" txt_f="13339">4 (4.4)</offsets></td><td char="(" align="char"><offsets xml_i="22070" xml_f="22077" txt_i="13340" txt_f="13347">2 (2.2)</offsets></td></tr><tr><td align="left" colspan="4"><offsets xml_i="22120" xml_f="22147" txt_i="13348" txt_f="13375">Number of organs involved, </offsets><italic><offsets xml_i="22155" xml_f="22156" txt_i="13375" txt_f="13376">n</offsets></italic><offsets xml_i="22165" xml_f="22169" txt_i="13376" txt_f="13380"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="22200" xml_f="22202" txt_i="13381" txt_f="13383"> 0</offsets></td><td char="(" align="char"><offsets xml_i="22233" xml_f="22240" txt_i="13384" txt_f="13391">1 (1.1)</offsets></td><td char="(" align="char"><offsets xml_i="22271" xml_f="22278" txt_i="13392" txt_f="13399">0 (0.0)</offsets></td><td char="." align="char" rowspan="4"><offsets xml_i="22321" xml_f="22327" txt_i="13400" txt_f="13406">0.8765</offsets></td></tr><tr><td align="left"><offsets xml_i="22358" xml_f="22360" txt_i="13407" txt_f="13409"> 1</offsets></td><td char="(" align="char"><offsets xml_i="22391" xml_f="22400" txt_i="13410" txt_f="13419">59 (64.8)</offsets></td><td char="(" align="char"><offsets xml_i="22431" xml_f="22440" txt_i="13420" txt_f="13429">64 (69.6)</offsets></td></tr><tr><td align="left"><offsets xml_i="22471" xml_f="22473" txt_i="13430" txt_f="13432"> 2</offsets></td><td char="(" align="char"><offsets xml_i="22504" xml_f="22513" txt_i="13433" txt_f="13442">23 (25.3)</offsets></td><td char="(" align="char"><offsets xml_i="22544" xml_f="22553" txt_i="13443" txt_f="13452">20 (21.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="22584" xml_f="22586" txt_i="13453" txt_f="13455"> 3</offsets></td><td char="(" align="char"><offsets xml_i="22617" xml_f="22624" txt_i="13456" txt_f="13463">8 (8.8)</offsets></td><td char="(" align="char"><offsets xml_i="22655" xml_f="22662" txt_i="13464" txt_f="13471">7 (7.6)</offsets></td></tr><tr><td align="left"><offsets xml_i="22693" xml_f="22695" txt_i="13472" txt_f="13474"> 4</offsets></td><td char="(" align="char"><offsets xml_i="22726" xml_f="22733" txt_i="13475" txt_f="13482">0 (0.0)</offsets></td><td char="(" align="char"><offsets xml_i="22764" xml_f="22771" txt_i="13483" txt_f="13490">1 (1.1)</offsets></td><td align="left"></td></tr></tbody></table><table-wrap-foot><p><italic><offsets xml_i="22847" xml_f="22851" txt_i="13492" txt_f="13496">ECOG</offsets></italic><offsets xml_i="22860" xml_f="22895" txt_i="13496" txt_f="13531"> Eastern Cooperative Oncology Group</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="22937" xml_f="23418" txt_i="13533" txt_f="14014">The FOLFOX4 group received a median of eight cycles of treatment and the TOMOX group received a median of six cycles of treatment. Reasons for treatment withdrawal included toxicity (27.5 vs. 33.7 % of patients, respectively), and PD (28.6 vs. 28.3 % of patients, respectively). In the FOLFOX4 group, the median relative dose intensity was 84 % for both 5-FU and oxaliplatin. In the TOMOX group, the median relative dose intensity was 92 % for raltitrexed and 93 % for oxaliplatin.</offsets></p></sec><sec id="Sec8"><title><offsets xml_i="23450" xml_f="23458" txt_i="14016" txt_f="14024">Efficacy</offsets></title><p><offsets xml_i="23469" xml_f="23518" txt_i="14025" txt_f="14074">ORR was 36.3 % for FOLFOX4 and 45.6 % for TOMOX (</offsets><italic><offsets xml_i="23526" xml_f="23527" txt_i="14074" txt_f="14075">p</offsets></italic><offsets xml_i="23536" xml_f="23554" txt_i="14075" txt_f="14093"> = 0.0032) (Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="23588" xml_f="23589" txt_i="14093" txt_f="14094">2</offsets></xref><offsets xml_i="23596" xml_f="23898" txt_i="14094" txt_f="14396">) and the non-inferiority of TOMOX in the primary endpoint when it is compared with FOLFOX4 was demonstrated. Disease control rate was similar for FOLFOX4 and TOMOX (69.3 and 74.9 %, respectively). With a median follow-up of 12.2 months, OS was 17.2 versus 15.7 months [HR 0.975 (95 % CI 0.655, 1.451; </offsets><italic><offsets xml_i="23906" xml_f="23907" txt_i="14396" txt_f="14397">p</offsets></italic><offsets xml_i="23916" xml_f="23933" txt_i="14397" txt_f="14414"> = 0.475)] (Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="23965" xml_f="23966" txt_i="14414" txt_f="14415">2</offsets></xref><offsets xml_i="23973" xml_f="24038" txt_i="14415" txt_f="14480">), PFS was 8.7 versus 7.7 months [HR 0.927 (95 % CI 0.65, 1.292; </offsets><italic><offsets xml_i="24046" xml_f="24047" txt_i="14480" txt_f="14481">p</offsets></italic><offsets xml_i="24056" xml_f="24073" txt_i="14481" txt_f="14498"> = 0.292)] (Fig. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="24105" xml_f="24106" txt_i="14498" txt_f="14499">3</offsets></xref><offsets xml_i="24113" xml_f="24165" txt_i="14499" txt_f="14551">), and response duration was 7.6 versus 6.4 months (</offsets><italic><offsets xml_i="24173" xml_f="24174" txt_i="14551" txt_f="14552">p</offsets></italic><offsets xml_i="24183" xml_f="24229" txt_i="14552" txt_f="14598"> = 0.372) for FOLFOX4 and TOMOX, respectively.</offsets><table-wrap id="Tab2"><label><offsets xml_i="24258" xml_f="24265" txt_i="14598" txt_f="14605">Table 2</offsets></label><caption><p><offsets xml_i="24285" xml_f="24304" txt_i="14605" txt_f="14624">Response evaluation</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"><offsets xml_i="24395" xml_f="24405" txt_i="14625" txt_f="14635">Response, </offsets><italic><offsets xml_i="24413" xml_f="24414" txt_i="14635" txt_f="14636">n</offsets></italic><offsets xml_i="24423" xml_f="24427" txt_i="14636" txt_f="14640"> (%)</offsets></th><th align="left" colspan="2"><offsets xml_i="24461" xml_f="24476" txt_i="14640" txt_f="14655">Treatment group</offsets></th></tr><tr><th align="left"><offsets xml_i="24507" xml_f="24516" txt_i="14655" txt_f="14664">FOLFOX4 (</offsets><italic><offsets xml_i="24524" xml_f="24525" txt_i="14664" txt_f="14665">n</offsets></italic><offsets xml_i="24534" xml_f="24540" txt_i="14665" txt_f="14671"> = 91)</offsets></th><th align="left"><offsets xml_i="24562" xml_f="24569" txt_i="14671" txt_f="14678">TOMOX (</offsets><italic><offsets xml_i="24577" xml_f="24578" txt_i="14678" txt_f="14679">n</offsets></italic><offsets xml_i="24587" xml_f="24593" txt_i="14679" txt_f="14685"> = 92)</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="24639" xml_f="24656" txt_i="14685" txt_f="14702">Complete response</offsets></td><td char="(" align="char"><offsets xml_i="24687" xml_f="24694" txt_i="14703" txt_f="14710">7 (7.7)</offsets></td><td char="(" align="char"><offsets xml_i="24725" xml_f="24732" txt_i="14711" txt_f="14718">4 (4.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="24763" xml_f="24779" txt_i="14719" txt_f="14735">Partial response</offsets></td><td char="(" align="char"><offsets xml_i="24810" xml_f="24819" txt_i="14736" txt_f="14745">26 (28.6)</offsets></td><td char="(" align="char"><offsets xml_i="24850" xml_f="24859" txt_i="14746" txt_f="14755">38 (41.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="24890" xml_f="24904" txt_i="14756" txt_f="14770">Stable disease</offsets></td><td char="(" align="char"><offsets xml_i="24935" xml_f="24944" txt_i="14771" txt_f="14780">30 (33.0)</offsets></td><td char="(" align="char"><offsets xml_i="24975" xml_f="24984" txt_i="14781" txt_f="14790">27 (29.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="25015" xml_f="25034" txt_i="14791" txt_f="14810">Progressive disease</offsets></td><td char="(" align="char"><offsets xml_i="25065" xml_f="25074" txt_i="14811" txt_f="14820">16 (17.6)</offsets></td><td char="(" align="char"><offsets xml_i="25105" xml_f="25114" txt_i="14821" txt_f="14830">12 (13.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="25145" xml_f="25158" txt_i="14831" txt_f="14844">Not evaluable</offsets></td><td char="(" align="char"><offsets xml_i="25189" xml_f="25198" txt_i="14845" txt_f="14854">12 (13.1)</offsets></td><td char="(" align="char"><offsets xml_i="25229" xml_f="25238" txt_i="14855" txt_f="14864">11 (12.0)</offsets></td></tr></tbody></table><table-wrap-foot><p><italic><offsets xml_i="25292" xml_f="25293" txt_i="14865" txt_f="14866">p</offsets></italic><offsets xml_i="25302" xml_f="25408" txt_i="14866" txt_f="14972"> = 0.0032 for non-inferiority of TOMOX considering overall response (complete response + partial response)</offsets></p></table-wrap-foot></table-wrap><fig id="Fig2"><label><offsets xml_i="25465" xml_f="25471" txt_i="14973" txt_f="14979">Fig. 2</offsets></label><caption><p><offsets xml_i="25491" xml_f="25533" txt_i="14979" txt_f="15021">Kaplan–Meier estimates of overall survival</offsets></p></caption><graphic xlink:href="12094_2012_843_Fig2_HTML" id="MO2"></graphic></fig><fig id="Fig3"><label><offsets xml_i="25641" xml_f="25647" txt_i="15022" txt_f="15028">Fig. 3</offsets></label><caption><p><offsets xml_i="25667" xml_f="25720" txt_i="15028" txt_f="15081">Kaplan–Meier estimates of time to disease progression</offsets></p></caption><graphic xlink:href="12094_2012_843_Fig3_HTML" id="MO3"></graphic></fig></p></sec><sec id="Sec9"><title><offsets xml_i="25838" xml_f="25844" txt_i="15084" txt_f="15090">Safety</offsets></title><p><offsets xml_i="25855" xml_f="26033" txt_i="15091" txt_f="15269">All patients, who received at least one dose of study medication were evaluable for toxicity assessments. The most common grades 3–4 adverse events (AEs) are summarized in Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="26067" xml_f="26068" txt_i="15269" txt_f="15270">3</offsets></xref><offsets xml_i="26075" xml_f="26195" txt_i="15270" txt_f="15390">. Grades 3–4 hematologic AEs were more frequent in the FOLFOX4 group than the TOMOX group [neutropenia: 34.1 vs. 5.4 % (</offsets><italic><offsets xml_i="26203" xml_f="26204" txt_i="15390" txt_f="15391">p</offsets></italic><offsets xml_i="26213" xml_f="26255" txt_i="15391" txt_f="15430"> &lt; 0.0001); leucopenia: 7.7 vs. 1.1 % (</offsets><italic><offsets xml_i="26263" xml_f="26264" txt_i="15430" txt_f="15431">p</offsets></italic><offsets xml_i="26273" xml_f="26316" txt_i="15431" txt_f="15474"> = 0.028); thrombocytopenia: 6.6 vs 1.1 % (</offsets><italic><offsets xml_i="26324" xml_f="26325" txt_i="15474" txt_f="15475">p</offsets></italic><offsets xml_i="26334" xml_f="26885" txt_i="15475" txt_f="16023"> = 0.064)]. Hepatic disorders (25.0 vs. 14.3 %) and asthenia (19.6 vs. 11.0 %) had a numerically higher incidence in the TOMOX group than the FOLFOX4 group, but the differences did not reach statistical significance. Regarding neurotoxicity, incidence of paresthesias grade &gt;2 was similar for FOLFOX and TOMOX groups, (7.7 and 6.5 %, respectively). Sixteen patients (18.6 %) in the FOLFOX4 group and 12 patients (13.0 %) in TOMOX group experienced serious AEs (SAEs). The difference in the incidence rate of SAEs was not statistically significant (</offsets><italic><offsets xml_i="26893" xml_f="26894" txt_i="16023" txt_f="16024">p</offsets></italic><offsets xml_i="26903" xml_f="27099" txt_i="16024" txt_f="16220"> = 0.393). There were two treatment-related deaths in the FOLFOX4 group (one due to neutropenic sepsis; one due to pancitopenia plus septic shock) and one in the TOMOX group (due to septic shock).</offsets><table-wrap id="Tab3"><label><offsets xml_i="27128" xml_f="27135" txt_i="16220" txt_f="16227">Table 3</offsets></label><caption><p><offsets xml_i="27155" xml_f="27212" txt_i="16227" txt_f="16284">Grades 3 and 4 hematologic and non-hematologic toxicities</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"><offsets xml_i="27303" xml_f="27329" txt_i="16285" txt_f="16311">Adverse events, % patients</offsets></th><th align="left" colspan="2"><offsets xml_i="27363" xml_f="27378" txt_i="16311" txt_f="16326">Treatment group</offsets></th><th align="left" rowspan="2"><italic><offsets xml_i="27420" xml_f="27421" txt_i="16326" txt_f="16327">p</offsets></italic><offsets xml_i="27430" xml_f="27436" txt_i="16327" txt_f="16333"> value</offsets></th></tr><tr><th align="left"><offsets xml_i="27467" xml_f="27476" txt_i="16333" txt_f="16342">FOLFOX4 (</offsets><italic><offsets xml_i="27484" xml_f="27485" txt_i="16342" txt_f="16343">n</offsets></italic><offsets xml_i="27494" xml_f="27500" txt_i="16343" txt_f="16349"> = 91)</offsets></th><th align="left"><offsets xml_i="27522" xml_f="27529" txt_i="16349" txt_f="16356">TOMOX (</offsets><italic><offsets xml_i="27537" xml_f="27538" txt_i="16356" txt_f="16357">n</offsets></italic><offsets xml_i="27547" xml_f="27553" txt_i="16357" txt_f="16363"> = 92)</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="27599" xml_f="27615" txt_i="16363" txt_f="16379">Thrombocytopenia</offsets></td><td char="." align="char"><offsets xml_i="27646" xml_f="27649" txt_i="16380" txt_f="16383">6.6</offsets></td><td char="." align="char"><offsets xml_i="27680" xml_f="27683" txt_i="16384" txt_f="16387">1.1</offsets></td><td align="left"><offsets xml_i="27705" xml_f="27710" txt_i="16388" txt_f="16393">0.064</offsets></td></tr><tr><td align="left"><offsets xml_i="27741" xml_f="27751" txt_i="16394" txt_f="16404">Leukopenia</offsets></td><td char="." align="char"><offsets xml_i="27782" xml_f="27785" txt_i="16405" txt_f="16408">7.7</offsets></td><td char="." align="char"><offsets xml_i="27816" xml_f="27819" txt_i="16409" txt_f="16412">1.1</offsets></td><td align="left"><offsets xml_i="27841" xml_f="27846" txt_i="16413" txt_f="16418">0.028</offsets></td></tr><tr><td align="left"><offsets xml_i="27877" xml_f="27888" txt_i="16419" txt_f="16430">Neutropenia</offsets></td><td char="." align="char"><offsets xml_i="27919" xml_f="27923" txt_i="16431" txt_f="16435">34.1</offsets></td><td char="." align="char"><offsets xml_i="27954" xml_f="27957" txt_i="16436" txt_f="16439">5.4</offsets></td><td align="left"><offsets xml_i="27979" xml_f="27989" txt_i="16440" txt_f="16447">&lt;0.0001</offsets></td></tr><tr><td align="left"><offsets xml_i="28020" xml_f="28028" txt_i="16448" txt_f="16456">Diarrhea</offsets></td><td char="." align="char"><offsets xml_i="28059" xml_f="28061" txt_i="16457" txt_f="16459">11</offsets></td><td char="." align="char"><offsets xml_i="28092" xml_f="28095" txt_i="16460" txt_f="16463">9.8</offsets></td><td align="left"><offsets xml_i="28117" xml_f="28119" txt_i="16464" txt_f="16466">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="28150" xml_f="28165" txt_i="16467" txt_f="16482">Nausea/vomiting</offsets></td><td char="." align="char"><offsets xml_i="28196" xml_f="28198" txt_i="16483" txt_f="16485">11</offsets></td><td char="." align="char"><offsets xml_i="28229" xml_f="28232" txt_i="16486" txt_f="16489">6.5</offsets></td><td align="left"><offsets xml_i="28254" xml_f="28256" txt_i="16490" txt_f="16492">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="28287" xml_f="28295" txt_i="16493" txt_f="16501">Asthenia</offsets></td><td char="." align="char"><offsets xml_i="28326" xml_f="28328" txt_i="16502" txt_f="16504">11</offsets></td><td char="." align="char"><offsets xml_i="28359" xml_f="28363" txt_i="16505" txt_f="16509">19.6</offsets></td><td align="left"><offsets xml_i="28385" xml_f="28387" txt_i="16510" txt_f="16512">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="28418" xml_f="28435" txt_i="16513" txt_f="16530">Hepatic disorders</offsets></td><td char="." align="char"><offsets xml_i="28466" xml_f="28470" txt_i="16531" txt_f="16535">14.3</offsets></td><td char="." align="char"><offsets xml_i="28501" xml_f="28503" txt_i="16536" txt_f="16538">25</offsets></td><td align="left"><offsets xml_i="28525" xml_f="28530" txt_i="16539" txt_f="16544">0.068</offsets></td></tr><tr><td align="left"><offsets xml_i="28561" xml_f="28572" txt_i="16545" txt_f="16556">Paresthesia</offsets></td><td char="." align="char"><offsets xml_i="28603" xml_f="28606" txt_i="16557" txt_f="16560">7.7</offsets></td><td char="." align="char"><offsets xml_i="28637" xml_f="28640" txt_i="16561" txt_f="16564">6.5</offsets></td><td align="left"><offsets xml_i="28662" xml_f="28664" txt_i="16565" txt_f="16567">NS</offsets></td></tr></tbody></table><table-wrap-foot><p><italic><offsets xml_i="28718" xml_f="28720" txt_i="16568" txt_f="16570">NS</offsets></italic><offsets xml_i="28729" xml_f="28758" txt_i="16570" txt_f="16599"> non-statistical significance</offsets></p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title><offsets xml_i="28826" xml_f="28841" txt_i="16602" txt_f="16617">Quality of life</offsets></title><p><offsets xml_i="28852" xml_f="29424" txt_i="16618" txt_f="17190">A total of 161 patients (88 %) were included in the QoL assessment. At baseline, there were no significant differences in scores for either composite physical/mental health measurements, or any individual components of SF-36, between the two groups. However, significant differences in SF-36 scores between the groups emerged during treatment. Both composite physical health and mental health scores were lower in the TOMOX group than the FOLFOX4 group after 6 weeks of treatment [changes in mean physical health score from baseline: +4.1 for FOLFOX4 and −2.93 for TOMOX (</offsets><italic><offsets xml_i="29432" xml_f="29433" txt_i="17190" txt_f="17191">p</offsets></italic><offsets xml_i="29442" xml_f="29544" txt_i="17191" txt_f="17293"> = 0.03); and changes in mean mental health score from baseline: +3.7 for FOLFOX4 and −2.1 for TOMOX (</offsets><italic><offsets xml_i="29552" xml_f="29553" txt_i="17293" txt_f="17294">p</offsets></italic><offsets xml_i="29562" xml_f="29646" txt_i="17294" txt_f="17378"> = 0.05)]. There were no differences in composite scores after 6 weeks of treatment.</offsets></p><p><offsets xml_i="29653" xml_f="29874" txt_i="17379" txt_f="17600">With respect to individual components of SF-36, there were significant differences in bodily pain and emotional role functioning scores in favor of FOLFOX4 after 6 and 12 weeks [bodily pain: +13.7 vs. +2.1 after 6 weeks (</offsets><italic><offsets xml_i="29882" xml_f="29883" txt_i="17600" txt_f="17601">p</offsets></italic><offsets xml_i="29892" xml_f="29934" txt_i="17601" txt_f="17643"> = 0.05); +15.9 vs. +1.85 after 12 weeks (</offsets><italic><offsets xml_i="29942" xml_f="29943" txt_i="17643" txt_f="17644">p</offsets></italic><offsets xml_i="29952" xml_f="30020" txt_i="17644" txt_f="17712"> = 0.01); emotional role functioning: +13.9 vs. −4.2 after 6 weeks (</offsets><italic><offsets xml_i="30028" xml_f="30029" txt_i="17712" txt_f="17713">p</offsets></italic><offsets xml_i="30038" xml_f="30079" txt_i="17713" txt_f="17754"> = 0.01); +7.1 vs. −11.9 after 12 weeks (</offsets><italic><offsets xml_i="30087" xml_f="30088" txt_i="17754" txt_f="17755">p</offsets></italic><offsets xml_i="30097" xml_f="30107" txt_i="17755" txt_f="17765"> = 0.05)].</offsets></p></sec></sec><sec id="Sec11" sec-type="discussion"><title><offsets xml_i="30168" xml_f="30178" txt_i="17768" txt_f="17778">Discussion</offsets></title><p><offsets xml_i="30189" xml_f="30380" txt_i="17779" txt_f="17970">Over the last decade, several phase II clinical trials have assessed TOMOX in patients with metastatic CRC and have demonstrated promising results in terms of ORR, survival and tolerability [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="30413" xml_f="30415" txt_i="17970" txt_f="17972">21</offsets></xref><offsets xml_i="30422" xml_f="30423" txt_i="17972" txt_f="17973">–</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="30456" xml_f="30458" txt_i="17973" txt_f="17975">25</offsets></xref><offsets xml_i="30465" xml_f="30467" txt_i="17975" txt_f="17977">, </offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="30500" xml_f="30502" txt_i="17977" txt_f="17979">28</offsets></xref><offsets xml_i="30509" xml_f="30510" txt_i="17979" txt_f="17980">–</offsets><xref ref-type="bibr" rid="CR30"><offsets xml_i="30543" xml_f="30545" txt_i="17980" txt_f="17982">30</offsets></xref><offsets xml_i="30552" xml_f="30908" txt_i="17982" txt_f="18338">]. However, few head-to-head studies have been published that compare TOMOX with established standard of care. In this study, first-line FOLFOX4 and TOMOX showed comparable efficacy in advanced CRC with acceptable tolerability profiles. These findings suggest that TOMOX could potentially be considered as a treatment option for patients with advanced CRC.</offsets></p><p><offsets xml_i="30915" xml_f="31037" txt_i="18339" txt_f="18461">The efficacy of TOMOX in advanced CRC observed in the current study was in accordance with previously published findings [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="31070" xml_f="31072" txt_i="18461" txt_f="18463">21</offsets></xref><offsets xml_i="31079" xml_f="31080" txt_i="18463" txt_f="18464">–</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="31113" xml_f="31115" txt_i="18464" txt_f="18466">25</offsets></xref><offsets xml_i="31122" xml_f="31124" txt_i="18466" txt_f="18468">, </offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="31157" xml_f="31159" txt_i="18468" txt_f="18470">28</offsets></xref><offsets xml_i="31166" xml_f="31167" txt_i="18470" txt_f="18471">–</offsets><xref ref-type="bibr" rid="CR30"><offsets xml_i="31200" xml_f="31202" txt_i="18471" txt_f="18473">30</offsets></xref><offsets xml_i="31209" xml_f="31301" txt_i="18473" txt_f="18565">]. The efficacy outcomes for the FOLFOX4 arm are in line with those achieved by De Gramont [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="31333" xml_f="31334" txt_i="18565" txt_f="18566">8</offsets></xref><offsets xml_i="31341" xml_f="31745" txt_i="18566" txt_f="18970">]. The median PFS reported by De Gramont et al. was 9 months, which is similar to the 8.7 months seen in our study. In contrast, the ORRs achieved in our study are lower (36.3 vs. 50.7 %). In the TOMOX arm of our study, the ORR, PFS and OS are within the general range obtained in previous trials. In three phase II clinical trials where patients with advanced CRC were treated with TOMOX, ORRs of 43 % [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="31778" xml_f="31780" txt_i="18970" txt_f="18972">24</offsets></xref><offsets xml_i="31787" xml_f="31796" txt_i="18972" txt_f="18981">], 46 % [</offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="31829" xml_f="31831" txt_i="18981" txt_f="18983">28</offsets></xref><offsets xml_i="31838" xml_f="31850" txt_i="18983" txt_f="18995">] and 54 % [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="31883" xml_f="31885" txt_i="18995" txt_f="18997">21</offsets></xref><offsets xml_i="31892" xml_f="32226" txt_i="18997" txt_f="19331">] were reported, compared to 45.7 % in our study. The median PFS values reported in the three studies (6.2, 8.2 and 10.3 months, respectively) are also in line with the 7.7 months observed in our study. Similarly, the median OS of 15.7 months in this study is comparable to the 14.6 and 14.5 months reported for two of these studies [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="32259" xml_f="32261" txt_i="19331" txt_f="19333">21</offsets></xref><offsets xml_i="32268" xml_f="32270" txt_i="19333" txt_f="19335">, </offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="32303" xml_f="32305" txt_i="19335" txt_f="19337">24</offsets></xref><offsets xml_i="32312" xml_f="32424" txt_i="19337" txt_f="19449">]. Furthermore, in a phase III clinical trial that compared TOMOX with oxaliplatin plus 5FU/LV in 216 patients [</offsets><xref ref-type="bibr" rid="CR31"><offsets xml_i="32457" xml_f="32459" txt_i="19449" txt_f="19451">31</offsets></xref><offsets xml_i="32466" xml_f="32527" txt_i="19451" txt_f="19512">], the TOMOX arm was superior in terms of ORR (29.1 vs. 17 % </offsets><italic><offsets xml_i="32535" xml_f="32536" txt_i="19512" txt_f="19513">p</offsets></italic><offsets xml_i="32545" xml_f="32637" txt_i="19513" txt_f="19605"> = 0.0437) although the oxaliplatin plus 5FU/LV arm ORR was lower than previously published.</offsets></p><p><offsets xml_i="32644" xml_f="33440" txt_i="19606" txt_f="20402">Both regimens were well tolerated, although there were some differences in the safety profiles of FOLFOX4 and TOMOX in this study. As expected, the incidence of neutropenia and leukopenia grade was higher in the FOLFOX arm and the incidence of hepatic disorders and asthenia was higher in the TOMOX arm, although without statistical significance. The number of treatment-related deaths was similar in both treatment arms (2 in FOLFOX arm vs. 1 in the TOMOX arm), and no unexpected AEs occurred. These data suggest that raltitrexed may be a tolerable treatment for advanced CRC, provided dose level and schedules are adjusted according to changes in CrCl and in response to the emergence of hematologic and non-hematologic toxicities. When compared with the data published from the PETACC1 study [</offsets><xref ref-type="bibr" rid="CR32"><offsets xml_i="33473" xml_f="33475" txt_i="20402" txt_f="20404">32</offsets></xref><offsets xml_i="33482" xml_f="33577" txt_i="20404" txt_f="20499">], the use of raltitrexed in our study did not increase the number of treatment-related deaths.</offsets></p><p><offsets xml_i="33584" xml_f="34241" txt_i="20500" txt_f="21157">In contrast to 5-FU, which requires a 22-h infusion for 2 consecutive days every 2 weeks and a central venous device, raltitrexed is administered as a 15-min intravenous infusion every 3 weeks. Given that TOMOX does not seem to be associated with any additional safety and tolerability concerns compared with FOLFOX4, the relative convenience of raltitrexed administration may make TOMOX an attractive option for first-line treatment of patients with advanced CRC, particularly in patients who find it difficult to meet the scheduling commitments for FOLFOX4 infusions, who cannot tolerate 5-FU-based regimens, or who cannot have a central venous catheter [</offsets><xref ref-type="bibr" rid="CR33"><offsets xml_i="34274" xml_f="34276" txt_i="21157" txt_f="21159">33</offsets></xref><offsets xml_i="34283" xml_f="34285" txt_i="21159" txt_f="21161">, </offsets><xref ref-type="bibr" rid="CR34"><offsets xml_i="34318" xml_f="34320" txt_i="21161" txt_f="21163">34</offsets></xref><offsets xml_i="34327" xml_f="34329" txt_i="21163" txt_f="21165">].</offsets></p><p><offsets xml_i="34336" xml_f="34909" txt_i="21166" txt_f="21739">Our study was limited because of the sample size estimated in the statistical plan was not achieved due to funding issues. However, the overall response rate, main endpoint of the study, was not affected and the results demonstrate the non-inferiority of TOMOX treatment when it is compare with FOLFOX4. There is a lack of power to reach significance in outcomes related to survival even though all HR point estimates were very close to 1, which indicates similarity between both regimens, and the non-inferiority of TOMOX could not be proven for these secondary endpoints.</offsets></p><p><offsets xml_i="34916" xml_f="35457" txt_i="21740" txt_f="22281">Finally, it is important to note that several monoclonal antibodies have been approved for clinical use in patients with advanced CRC: the antivascular endothelial growth factor antibody bevacizumab and the anti-epidermal growth factor receptor antibodies cetuximab and panitumumab. However, targeted therapies were not standard treatment options when the current study was running. Further studies will be required to guide the optimal application of TOMOX in relation to the range of other treatment options now available for advanced CRC.</offsets></p><p><offsets xml_i="35464" xml_f="35956" txt_i="22282" txt_f="22774">In conclusion, our study indicates that the TOMOX regimen appears similar to FOLFOX in terms of efficacy and tolerability as first-line treatment for advanced CRC. Furthermore, the ambulatory administration schedule could provide greater convenience for a large number of patients. However, confirmatory phase III studies are required to fully establish the efficacy and safety profile of the regimen. Combinations of TOMOX with monoclonal antibodies require investigation in clinical trials.</offsets></p></sec></body><back><ack><title>Conflict of interest</title><p>The authors declare no potential conflicts of interest.</p><sec id="d29e1212"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">International Agency for Research on Cancer (2008) World Cancer Report 2008. <ext-link ext-link-type="uri" xlink:href="http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php">http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php</ext-link></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname><given-names>P</given-names></name><name><surname>Ferlay</surname><given-names>P</given-names></name></person-group><article-title>Cancer incidence and mortality in Europe 2004</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><fpage>481</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdi098</pub-id><pub-id pub-id-type="pmid">15718248</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Sargent</surname><given-names>D</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name><etal></etal></person-group><article-title>Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>7</issue><fpage>1209</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.11.037</pub-id><pub-id pub-id-type="pmid">15051767</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>RTT</given-names></name><name><surname>Au</surname><given-names>GKH</given-names></name><name><surname>Yau</surname><given-names>CC</given-names></name></person-group><article-title>Chemotherapy for advanced colorectal carcinoma: fact and fable</article-title><source>Coll Radiol</source><year>2002</year><volume>5</volume><fpage>143</fpage><lpage>154</lpage></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pessino</surname><given-names>A</given-names></name><name><surname>Sobrero</surname><given-names>A</given-names></name></person-group><article-title>Optimal treatment of metastatic colorectal cancer</article-title><source>Expert Rev Anticancer Ther</source><year>2006</year><volume>6</volume><issue>5</issue><fpage>801</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1586/14737140.6.5.801</pub-id><pub-id pub-id-type="pmid">16759170</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machover</surname><given-names>D</given-names></name></person-group><article-title>A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma</article-title><source>Cancer</source><year>1997</year><volume>80</volume><issue>7</issue><fpage>1179</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19971001)80:7&lt;1179::AID-CNCR1&gt;3.0.CO;2-G</pub-id><pub-id pub-id-type="pmid">9317168</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gramont</surname><given-names>A</given-names></name><name><surname>Bosset</surname><given-names>JF</given-names></name><name><surname>Milan</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>808</fpage><lpage>815</lpage><pub-id pub-id-type="pmid">9053508</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gramont</surname><given-names>A</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Seymour</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer</article-title><source>J Clin Oncol</source><year>2002</year><volume>18</volume><fpage>2938</fpage><lpage>2947</lpage><pub-id pub-id-type="pmid">10944126</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Engstrom PF, Arnoletti JP, Benson AB et al (2009) NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. JNCCN 7(8):778–831</mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Engstrom PF, Arnoletti JP, Benson AB et al (2009) NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. JNCCN 7(8):838–881</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zalcberg</surname><given-names>JR</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Custsem</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>716</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">8622016</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrugia</surname><given-names>DC</given-names></name><name><surname>Ford</surname><given-names>HE</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>792</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">12576452</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beale</surname><given-names>P</given-names></name><name><surname>Judson</surname><given-names>I</given-names></name><name><surname>Hanwell</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Metabolism, excretion and pharmacokinetics of a single dose of (14C)-raltitrexed in cancer patient</article-title><source>Cancer Chemother Pharmacol</source><year>1996</year><volume>42</volume><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1007/s002800050787</pub-id><pub-id pub-id-type="pmid">9619761</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Zalcberg</surname><given-names>JR</given-names></name><name><surname>Rath</surname><given-names>U</given-names></name><etal></etal></person-group><article-title>Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer</article-title><source>Ann Oncol</source><year>1996</year><volume>7</volume><fpage>961</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.annonc.a010800</pub-id><pub-id pub-id-type="pmid">9006748</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cocconi</surname><given-names>G</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Cutsem</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Open randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>2943</fpage><lpage>2952</lpage><pub-id pub-id-type="pmid">9738562</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maughan</surname><given-names>TS</given-names></name><name><surname>James</surname><given-names>RD</given-names></name><name><surname>Kerr</surname><given-names>DJ</given-names></name><etal></etal></person-group><article-title>Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomized trial</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>1555</fpage><lpage>1563</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)08514-8</pub-id><pub-id pub-id-type="pmid">12047964</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Pazdur R, Vicent M (1997) Raltitrexed (Tomudex) vs 5-fluorouracil and leucovorin (5FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter North American trial. Proc Am Clin Oncol 16:228 (abstract 801)</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Topham</surname><given-names>C</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>A patient preference study comparing raltitrexed (‘Tomudex’) and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes</article-title><source>Eur J Cancer Care</source><year>1999</year><volume>8</volume><fpage>154</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2354.1999.00152.x</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fizazi</surname><given-names>K</given-names></name><name><surname>Ducreux</surname><given-names>M</given-names></name><name><surname>Ruffie</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Phase I dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2293</fpage><lpage>2300</lpage><pub-id pub-id-type="pmid">10829050</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fizazi</surname><given-names>K</given-names></name><name><surname>Caliandro</surname><given-names>R</given-names></name><name><surname>Soulié</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma</article-title><source>Eur J Cancer</source><year>2000</year><volume>36</volume><fpage>1514</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(00)00139-8</pub-id><pub-id pub-id-type="pmid">10930799</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Bennouna</surname><given-names>J</given-names></name><name><surname>Paillot</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><fpage>1072</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdf183</pub-id><pub-id pub-id-type="pmid">12176786</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Kornek</surname><given-names>GV</given-names></name><name><surname>Ulrich-Pur</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma</article-title><source>Cancer</source><year>2001</year><volume>91</volume><fpage>1264</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(20010401)91:7&lt;1264::AID-CNCR1127&gt;3.0.CO;2-X</pub-id><pub-id pub-id-type="pmid">11283925</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Kornek</surname><given-names>GV</given-names></name><name><surname>Schuell</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>709</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1023/A:1011194712661</pub-id><pub-id pub-id-type="pmid">11432632</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neri</surname><given-names>B</given-names></name><name><surname>Doni</surname><given-names>L</given-names></name><name><surname>Fulignati</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial</article-title><source>Anti Cancer Drugs</source><year>2002</year><volume>13</volume><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1097/00001813-200208000-00006</pub-id><pub-id pub-id-type="pmid">12187328</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Graziano</surname><given-names>F</given-names></name><name><surname>Ferrau</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><fpage>716</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdf091</pub-id><pub-id pub-id-type="pmid">12075739</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>EL</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name></person-group><article-title>Nonparametric estimation from incomplete observation</article-title><source>J Am Stat Assoc</source><year>1958</year><volume>53</volume><fpage>457</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1080/01621459.1958.10501452</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>DR</given-names></name></person-group><article-title>Regression models and life tables</article-title><source>J R Stat Soc B</source><year>1972</year><volume>34</volume><fpage>187</fpage><lpage>220</lpage></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Massacesi</surname><given-names>C</given-names></name><name><surname>D′Angelillo</surname><given-names>RM</given-names></name><etal></etal></person-group><article-title>Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer</article-title><source>Med Oncol</source><year>2004</year><volume>21</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1385/MO:21:1:59</pub-id><pub-id pub-id-type="pmid">15034215</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortinovis</surname><given-names>D</given-names></name><name><surname>Bajetta</surname><given-names>E</given-names></name><name><surname>Bartolomeo</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer</article-title><source>Tumori</source><year>2004</year><volume>90</volume><issue>2</issue><fpage>186</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">15237580</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feliu</surname><given-names>J</given-names></name><name><surname>Castañón</surname><given-names>C</given-names></name><name><surname>Salud</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Phase II randomized trial of raltitrexed oxaliplatin vs raltitrexed irinotecan as first-line treatment in advanced colorectal cancer</article-title><source>Br J Cancer</source><year>2005</year><volume>93</volume><fpage>1230</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6602860</pub-id><pub-id pub-id-type="pmid">16265344</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Wang J, Li J, Qin S et al (2007) Randomized multicenter phase III trial of oxaliplatin plus raltitrexed compared to oxaliplatin plus fluorouracil and leucovorin treatment in recurrent and metastatic colorectal cancer. Nonparametric estimation from incomplete observation. J Clin Oncol 25:18S (Suppl). Abstract 4102</mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popov</surname><given-names>I</given-names></name><name><surname>Carrato</surname><given-names>A</given-names></name><name><surname>Sobrero</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)</article-title><source>Eur J Cancer</source><year>2008</year><volume>44</volume><fpage>2204</fpage><lpage>2211</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.07.002</pub-id><pub-id pub-id-type="pmid">18707870</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volk</surname><given-names>J</given-names></name><name><surname>Reinke</surname><given-names>F</given-names></name><name><surname>Kuilenburg</surname><given-names>AB</given-names></name><etal></etal></person-group><article-title>Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>569</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1023/A:1011178111295</pub-id><pub-id pub-id-type="pmid">11398894</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luján</surname><given-names>J</given-names></name><name><surname>García de Burgos</surname><given-names>F</given-names></name><name><surname>Jordán</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Angina en relación con 5-fluorouracilo</article-title><source>Rev Esp Cardiol</source><year>2002</year><volume>55</volume><issue>7</issue><fpage>764</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">12113705</pub-id></mixed-citation></ref></ref-list></back></article>